Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 2017

View Archived Issues

Synthon opens phase III trial of SYD-985 in HER2-positive advanced breast cancer

Everfront studies Cerebraca wafer with adjuvant temozolomide in recurrent high-grade glioma

Patient recruitment ongoing in phase I trial of TRK-750

Adverum Biotechnologies begins phase I/II ADVANCE trial in alpha-1 antitrypsin deficiency

FDA grants fast track designation for CA-008 as treatment of postsurgical pain

Positive topline results from phase II study of SAGE-217 in patients with MDD

MeiraGTx drug for LCA2 obtains FDA rare pediatric disease designation

CCL-20 S64C demonstrates efficacy in IL-23-dependent mouse model of psoriasis

FDA gives fast track designation to Aptinyx's NYX-783

AVEO Oncology gives update on tivozanib and ficlatuzumab studies

Xoma licenses XOMA-358 to Rezolute

Phase IIb study of eryaspase for AML does not meet primary endpoint

GlaxoSmithKline patents BRD4 inhibitors

Roche presents new EAAT3 inhibitors for glaucoma

FDA grants fast track designation to Rhizen's RP-6530 for relapsed/refractory PTCL

Enanta Pharmaceuticals discovers bile acid receptor agonists

Merck & Co. divulges new FFA4 receptor agonists

Novel CBP inhibitors presented by Genentech and Constellation Pharmaceuticals

Metacrine closes series B financing to advance MET-409

FDA approves Sunovion's Lonhala Magnair

Ayala Pharmaceuticals obtains rights to two BMS compounds

IDMC recommends continuation of phase IIa study of milciclib in HCC

OG-L002 shows promising in vivo results for the treatment of sickle cell disease

GT Biopharma initiates phase I study of GTP-004 for the treatment of myasthenia gravis

Pieris Pharmaceuticals cleared to begin clinical testing of PRS-060

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 12, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...